Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
63
resultados
Última actualización
28/08/2026 [06:45:00]
Resumen de: AU2026205213A1
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in 5 a mammal, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, including but not limited to leukemia, myelodysplastic syndrome (MDS), and myeloproliferative neoplasms (MPN); and diabetes. ul u l
Resumen de: AU2026214088A1
#48183531_1 PHARMACEUTICAL FORMULATIONS OF BRUTON'S TYROSINE KINASE INHIBITOR Abstract Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor I-((R)-3-(4-amino-3-(4-phenoxyphenyl)-IH-pyrazolo 3,4-dpyrimidin- l-yl)piperidin-l-yl)prop-2-en-I-one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. PHARMACEUTICAL FORMULATIONS OF BRUTON'S TYROSINE KINASE INHIBITOR Abstract Formulation A Formulation B Mean Ibrutinib Plasma Concentration (ng/mL) Formulation C Formulation D 0 6 12 18 24 Nominal Time Post-Dose (h) ug ' u g b s t r a c t o r m u l a t i o n o r m u l a t i o n Mean Ibrutinib Plasma Concentration (ng/mL)
Resumen de: US20260242503A1
Disclosed are methods of treating a subject having high-risk multiple myeloma, methods of achieving negative minimal residual disease status in a subject having multiple myeloma, and methods of predicting a likelihood of, or decreasing a risk of, relapse and/or disease progression in a subject having multiple myeloma.
Resumen de: US20260242391A1
Disclosed herein are methods for using an antimalarial endoperoxide compound, such as artemisinin, intreating a subject suffering from myelodysplastic syndromes (MDS), and in slowing or preventing the progression of MDS in the subject to development of acute myeloid leukemia (AML).
Resumen de: US20260241027A1
0000 The present disclosure discloses a use of anti-CD20 ADC in the preparation of a drug for treating NHL, and the drug has excellent clinical efficacy and safety in treating a R/R NHL patient after receiving at least two standard treatments.
Resumen de: US20260242496A1
0000 An aqueous pharmaceutical formulation having improved stability includes denosumab and a poloxamer, and preferably a histidine buffer and/or sugar or sugar alcohol. The formulation is for use in treating or preventing osteoporosis, loss of bone mass, skeletal-related events associated with multiple myeloma, solid tumor bone metastases, giant cell tumors of the bone or hypercalcemia.
Resumen de: US20260241033A1
The present disclosure is directed to CRISPR-related systems and components for targeting, editing, and/or modulating expression of a FLI-1 (Friend virus leukemia integration 1 transcription factor; Fli-1 Proto-Oncogene, ETS Transcription Factor) gene. The present disclosure also relates to methods and applications thereof in connection with engineered cells including T cells or T cell precursors.
Resumen de: AU2026210818A1
The present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD28, and a second antigen- binding molecule that specifically binds human CD-22. In certain embodiments, the bispecific antigen- binding molecules of the present invention are capable of inhibiting the growth of tumors expressing CD-22, such as B-cell lymphomas. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an up-regulated or induced targeted immune response is desired and/or therapeutically beneficial. ul u l
Resumen de: WO2026173613A2
The present disclosure provides nanobodies that specifically target blood cancer antigens such as TIM-3, CLEC12a, BCMA, CD38, CD229, SLAMF7, and BAFF-R, and methods of using the same to treat blood cancers such as AML and multiple myeloma. The present disclosure also provides engineered immune cells comprising nanobody-based chimeric antigen receptors (CARs) that include nanobodies that specifically target blood cancer antigens such as TIM-3, CLEC12a, BCMA, CD38, CD229, SLAMF7, and BAFF-R, and methods of using the same to treat blood cancers such as AML and multiple myeloma.
Resumen de: WO2026174182A1
Pyrazolopyrimidines and imidazopyrazine compounds of Formulas (I) and (II) are provided. The compounds can be used to target OTU domain-containing protein 7A (OTUD7A), e.g., to block and/or reduce OTUD7A-mediated deubiquitination of Ewing sarcoma breakpoint region 1-Friend leukemia virus integration 1 transcription factor (EWS-FLI1). Methods of treating conditions dependent on FLI1, including Ewing sarcoma, leukemia, and other cancers, by administering the compounds, are also described.
Resumen de: WO2026171195A1
The present invention provides a pharmaceutical composition comprising a piperidine ring compound, and a use thereof. Specifically provided is a pharmaceutical composition, comprising a compound represented by formula (I) or a pharmaceutically acceptable salt thereof and CHOP or CHOEP. The pharmaceutical composition provided by the present invention has synergistic advantages, and has good therapeutic efficacy against lymphoma.
Resumen de: AU2025227271A1
This application pertains to the use of Compound (A): or a pharmaceutically acceptable salt thereof, for the treatment of various diseases or disorders, including, for example, advanced non-Hodgkin lymphoma (NHL), relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL), transformed follicular lymphoma, nodal T-follicular helper cell lymphoma (nTFHL), relapsed/refractory (R/R) nodal T-follicular helper cell lymphoma, nodal T-follicular helper cell lymphoma - angioimmunoblastic type (nTFHL- Al) / advanced angioimmunoblastic T-cell lymphoma (AITL), or relapsed/refractory (R/R) nodal T-follicular helper cell lymphoma - angioimmunoblastic type (nTFHL-AI) / angioimmunoblastic T-cell lymphoma (AITL).
Resumen de: WO2026174057A1
The present disclosure provides for compositions comprising a combination of marine biomass extracts for use in the treatment of cancer, where the cancer is a leukemia, a bladder cancer, a gastric cancer, a breast cancer, a multiple myeloma, a lung cancer, or a pancreatic cancer. Further provided herein are biomass compositions having extracts from Holothuria scabra, Holothuria nobilis, Heliocidaris erythrogramma, Styela clava, and Sargassum pallidum. Moreover, in such compositions the majority components may be extracts from sea cucumber.
Resumen de: WO2026174042A1
Provided are compounds of the structural Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with ALK.
Resumen de: GB2704112A
A compound of formula (I), or a pharmaceutically acceptable salt or hydrate thereof, is provided, wherein R groups are as defined herein, X-Y is -NHSO2-, A is selected from: a C4-C8-cycloalkyl group; a bicyclic C5-C12-cycloalkyl group; and a C4-C8-cycloalkyl group fused to an aryl or heteroaryl group; each of which is optionally substituted by one or more R4 groups; R1 is haloalkyl or OR3; R2 is H or halo; R3 is alkyl or benzyl; and each R4 is independently alkyl or halo. B is NR6R7, wherein R6 and R7 are linked to form a polycyclic group containing at least one spiro carbon, and which polycyclic group optionally contains one or more groups independently selected from NR35, CO, O, S, SO and SO2, and is optionally further substituted by one or more R5 groups; each R5 is independently selected from COOH, CONR8R9, CONHSO2R10, NR30R31, CO2-alkyl, OH, alkyl, halo, haloalkyl, alkoxy, aminoalkyl, and hydroxyalkyl. The compounds modulate ERAP2 and are useful in treating proliferative, viral, immune or inflammatory disorders, particularly cancer or leukaemia. The compounds stimulate a neo-antigen directed immune response. Methods of producing antigen-presenting cells and immunogenic compositions are also disclosed. Exemplified compounds include N-(2-(cyclohexylamino)-5-(trifluoromethyl)phenyl)-2,4-dioxo-1,3,7-triazaspiro4,5decane-7-sulfonamide No Figure
Resumen de: WO2025080543A1
Provided herein are methods of predicting the responsiveness of a lymphoma patient to a cancer treatment. Also provided herein are methods of treating a lymphoma patient based on predicting the responsiveness of the lymphoma patient to a cancer treatment.
Resumen de: WO2025080911A1
The present disclosure is directed to methods of treating multiple myeloma. The present disclosure is directed to methods of treating newly diagnosed multiple myeloma in a subject in need thereof, for example, by subcutaneously administering to the subject a pharmaceutical composition comprising an anti-CD38 antibody in combination with bortezomib, lenalidomide, and dexamethasone.
Resumen de: US20260234248A1
0000 This invention provides a method for treating a subject afflicted with a hematologic malignancy comprising administering to the subject an agent targeting a hematologic malignancy-associated antigen, wherein the subject has a low peripheral cancerous cell burden. This invention also provides a method for treating a subject afflicted with a hematologic malignancy and having a high peripheral cancerous cell burden, comprising (i) medically lowering the subject's peripheral cancerous cell burden, and (ii) while the subject's peripheral cancerous cell burden is still low, administering to the subject an agent targeting a hematologic malignancy-associated antigen. Particularly envisioned are the subject methods for treating acute myeloid leukemia using an anti-CD33 antibody labeled with an alpha-emitting isotope, such as <225>Ac-HuM195.
Resumen de: US20260234630A1
0000 Provided herein are methods of treating multiple myeloma, including multiple myeloma that is resistant to at least one therapeutic agent, comprising administering to a subject with multiple myeloma an inhibitor of Ubiquitin-Like with PHD and Ring Finger Domains 1 (UHRF1).
Resumen de: US20260234207A1
0000 The present invention belongs to the field of biopharmaceuticals. Provided in the present invention are keratin YK93-8, a nucleic acid molecule encoding same, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or a host cell having the nucleic acid molecule integrated into the genome, as well as a method for preparing keratin YK93-8 and a pharmaceutical composition of keratin YK93-8. Further provided is the use of the above-mentioned keratin YK93-8 and other products in the preparation of drugs, such as a drug for treating hyperplasia of prostate, lymphoma, melanoma, breast cancer, lung cancer and uterine myoma, an analgesic, a lactation drug and a coagulant.
Resumen de: US20260232681A1
0000 Described herein is N-4-4-(4-morpholinyl)-7H-pyrrolo2,3-dpyrimidin-6-ylphenyl-4-3(R)-(1-oxo-2-propen-1-yl)amino-1-piperidinylmethyl-2-pyridinecarboxamide (Compound A) (Formula I), including crystalline forms, solvates, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions or pharmaceutical formulations that include the compound, as well as methods of using the compound, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, diabetes, and inflammatory diseases or conditions.
0000
Resumen de: US20260232807A1
A method of impairing cancer cell growth in a mammal having leukemia or lymphoma is disclosed, the method including administering to the mammal a pharmaceutical composition comprising a pharmacologically active amount of (+)-BAY K8644 as a monotherapy or in combination with the tyrosine kinase inhibitor, Ibrutinib.
Resumen de: US20260232732A1
The present invention provides therapeutics for the treatment of CCR9-positive cancers such as T-cell acute lymphoblastic leukemia. In particular, the present invention provides a CCR9 targeting moiety. The present invention furthermore relates to a CCR9 targeting moiety comprising a further targeting moiety, preferably a CD1a targeting moiety, a dual CAR comprising a CCR9 and a CD1a targeting moiety, their use in the treatment of CCR9 and/or CD1a positive cancers, and the use of a CCR9 targeting moiety and a separate CD1a targeting moiety for such treatment.
Resumen de: US20260234129A1
The present invention relates to a novel imidazole derivative and a pharmaceutical composition for treating protein kinase-associated diseases, comprising same as an active ingredient. More specifically, the present invention relates to a novel imidazole derivative and a pharmaceutical composition comprising same as an active ingredient, the derivative inhibiting protein kinase activity so as to prevent or treat cancer diseases. In addition, the compound and the pharmaceutical composition, comprising same as an active ingredient, of the present invention, effectively inhibit FLT3 kinase activity, and thus can be effectively used for preventing or treating mutant FLT3-associated diseases, particularly acute myeloid leukemia.
Nº publicación: US20260234146A1 13/08/2026
Solicitante:
KIND PHARMACEUTICAL [CN]
Kind Pharmaceutical
Resumen de: US20260234146A1
The present application relates to use of a hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHI) in rare anemia. Specifically disclosed in the present application is use of certain hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) in the treatment of anemia of myelodysplastic syndromes (MDS anemia), beta-thalassemia (β-thalassemia), and/or sickle cell disease (sickle cell anemia, SCD anemia).
BOPI
Sede Electrónica
